obesity drug news today october 2025 glp-1 trends 2025: real-world data, patient outcomes & future therapies GLP-1 Weight-Loss Drug Demonstration Begins
Description
This gap has catalyzed significant R&D investment in muscle-sparing adjuncts, including myostatin inhibitors and ActRII pathway modulators that could be combined with GLP-1 agonists to preserve lean mass while maintaining fat loss efficacy
Adults who were obese as children have increased mortality independent of adult weight
Weight management can be influenced by many non-modifiable factors like genetic predispositions, age, and ethnicity
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials
adults hit these targets
Diabetes Care 44 , 10201026 (2021) S.C
